Regen BioPharma Files 2024 10-K

Ticker: RGBPP · Form: 10-K · Filed: May 13, 2025 · CIK: 1589150

Sentiment: neutral

Topics: 10-K, annual-report, pharmaceuticals

TL;DR

Regen BioPharma filed its 2024 10-K. Check financials.

AI Summary

Regen BioPharma Inc. filed its 10-K for the fiscal year ending September 30, 2024, reporting on its operations and financial condition. The company, incorporated in Nevada, is based in La Mesa, California. This filing provides a comprehensive overview of its business, risks, and financial performance for the period.

Why It Matters

This 10-K filing provides investors and stakeholders with a detailed look into Regen BioPharma's financial health and strategic direction for the fiscal year 2024, crucial for understanding the company's performance and future prospects.

Risk Assessment

Risk Level: medium — As a pharmaceutical company, Regen BioPharma faces inherent risks related to drug development, regulatory approvals, and market competition.

Key Numbers

Key Players & Entities

FAQ

What are Regen BioPharma's primary business activities?

The filing indicates Regen BioPharma Inc. operates in the Pharmaceutical Preparations industry (SIC code 2834).

When did Regen BioPharma file its 10-K for the fiscal year ending September 30, 2024?

The 10-K was filed on May 13, 2025.

Where is Regen BioPharma Inc. located?

The company's business and mailing address is 4700 Spring St #304, La Mesa, CA 91942.

What is the state of incorporation for Regen BioPharma Inc.?

Regen BioPharma Inc. is incorporated in Nevada (NV).

What types of preferred stock are mentioned in the filing?

The filing mentions Series A Preferred Stock, Series AA Preferred Stock, Series M Preferred Stock, and Series NC Preferred Stock.

Filing Details

This Form 10-K (Form 10-K) was filed with the SEC on May 13, 2025 regarding Regen BioPharma Inc (RGBPP).

View full filing on EDGAR

View Full Filing

View this 10-K filing on SEC EDGAR

View on Read The Filing